Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06847191 · ClinicalTrials.gov registry record · Phase 2

NE3107 in Adults With Neurological Symptoms of Long COVID

A Phase 2 study of Long COVID, sponsored by BioVie.

Recruiting
Registry status
Phase 2
Development phase
208
Enrollment target
20
Study locations

NCT06847191 is a Phase 2 study of Long COVID that is actively recruiting participants, run by BioVie. The registered enrollment target is 208 participants, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06847191, a Phase 2 study of Long COVID, is actively recruiting participants, sponsored by BioVie.

RECRUITING
Registry status
Phase 2
Development phase
208 participants
Enrollment target
20
Study locations

Study Summary

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call

Conditions Studied

Long COVID

Interventions

  • DRUG Placebo
  • DRUG NE3107

Study Locations (20)

California

  • Stanford University - Palo Alto
  • UCSF - San Francisco

Illinois

  • Illinois Research Network University of Illinois at Chicago - Chicago
  • Northwestern University - Chicago

Texas

  • Zenos Clinical Research - Dallas
  • University of Texas health Science Center at San Antonio - San Antonio

Colorado

  • University of Colorado - Aurora

Connecticut

  • Yale University - New Haven

Florida

  • Clinical Trial Site - Jacksonville

Georgia

  • Centricity Research - Columbus

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 208 participants
Start Date 2025-04-29
Est. Completion 2026-08
Phase Phase 2

Sponsor

BioVie

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06847191

The ClinicalTrials.gov registry entry for NCT06847191 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (90% lower). The listed sponsor is BioVie, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06847191 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Illinois, Texas.

Frequently Asked Questions

What is clinical trial NCT06847191 about?

NCT06847191 is a clinical study titled "NE3107 in Adults With Neurological Symptoms of Long COVID". Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fa...

What is the current status of trial NCT06847191?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2025-04-29. Estimated completion is 2026-08.

What conditions does trial NCT06847191 study?

This clinical trial studies the following conditions: Long COVID.

What interventions are being tested in trial NCT06847191?

The interventions under investigation include: Placebo (DRUG), NE3107 (DRUG).

Who is sponsoring clinical trial NCT06847191?

This trial is sponsored by BioVie, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06847191 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Long COVID

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.